MERIT MEDICAL SYSTEMS (MMSI)

Teleflex Inc

This competitor is identified as one of the primary competitors in the peripheral intervention market, alongside others, and operates in the global medical technology marketplace characterized by rapid technological advancement and customer demands for price reductions. "

Cook Medical Incorporated

This competitor is mentioned as a primary competitor in both the peripheral intervention and cardiac intervention markets, and also competes in the oncology and endoscopy markets. It is noted for its presence in specific product lines and geographies. "

Medtronic PLC

This competitor is highlighted as a primary competitor in the peripheral intervention, cardiac intervention, and spine markets. It is one of the larger companies with extensive resources in the medical device industry. "

Boston Scientific Corp

This competitor is listed as a primary competitor in the peripheral intervention, cardiac intervention, and endoscopy markets. It is part of the competitive landscape in the global medical technology marketplace. "

Becton Dickinson and Co

This competitor is identified as a primary competitor in the peripheral intervention, cardiac intervention, and oncology markets. It is noted for its involvement in various product lines. "

Abbott Laboratories

This competitor is mentioned as a primary competitor in the cardiac intervention market, competing in the global medical technology marketplace. "

Terumo Corporation

This competitor is listed as a primary competitor in the cardiac intervention market, operating in the highly competitive medical device industry. "

Edwards Lifesciences Corp

This competitor is identified as a primary competitor in the cardiac intervention market, contributing to the competitive dynamics of the industry. "

Stryker Corp

This competitor is mentioned as a primary competitor in the spine market, competing in the global medical technology marketplace. "

Johnson & Johnson

This competitor is listed as a primary competitor in the spine market, operating as one of the larger companies in the medical device industry. "

Hologic Inc

This competitor is identified as a primary competitor in the oncology market, contributing to the competitive landscape in this segment. "

Endomagnetics Ltd.

This competitor is mentioned as a primary competitor in the oncology market, operating in specific product lines. "

Argon Medical Devices, Inc.

This competitor is listed as a primary competitor in the oncology market, contributing to the competitive dynamics in this segment. "

Getinge AB

This competitor is identified as a primary competitor in the endoscopy market, operating in the global medical technology marketplace. "

Olympus Corporation

This competitor is mentioned as a primary competitor in the endoscopy market, contributing to the competitive landscape in this segment. "

Biolife Delaware, L.L.C.

2025

Merit Medical acquired Biolife through a merger for $120 million in cash plus $6.3 million in adjustments, making it a wholly owned subsidiary that expands its portfolio of patented hemostatic devices (StatSeal and WoundSeal) in a $350 million global market opportunity. " " " " "

EndoGastric Solutions, Inc.

2024

Merit Medical acquired EndoGastric Solutions for approximately $105 million, financing the deal via long‐term debt and obtaining the EsophyX® Z+ device to strengthen its gastrointestinal product offerings in a $2 billion market, with integration agreements and updated revenue guidance. " " " " " "

Cook Medical's Lead Management Portfolio

2024

Merit Medical acquired the Lead Management Portfolio for about $210 million through cash and credit facility borrowings, enhancing its electrophysiology and cardiac rhythm management business with added differentiated products and transition services over a two‐year period. " " " " "

Scholten Surgical Instruments, Inc. (SSI)

2024

Merit Medical acquired SSI’s assets for an upfront $3 million plus deferred payments totaling $3 million, obtaining the Bioptome, Novatome, and Sensatome devices, with the payments recorded as a developed technology intangible asset amortized over eight years. " " "

AngioDynamics, Inc.

2023

Merit Medical acquired a portfolio including dialysis catheter products and the BioSentry® Biopsy Tract Sealant System for $100 million, financed with debt and allocated among developed technology, trademarks, and goodwill to bolster its dialysis and biopsy market presence. " " " " "

Bluegrass Vascular Technologies, Inc.

2023

Merit Medical acquired Bluegrass’s Surfacer® Inside-Out® Access Catheter System for $32.7 million (plus inclusion of a $245,000 equity investment), with assets allocated to inventories, developed technology, trademarks, and goodwill—further strengthening its cardiovascular segment. " " " "

Restore Endosystems, LLC

2022

Merit Medical acquired Restore Endosystems’ Bifurcated Stent System by paying $3 million upfront with additional milestone-based payments, accounting the transaction as an asset purchase with in-process R&D expense to augment its cardiovascular offerings. " " "

Fluidx Medical Technology, Inc.

2022

Merit Medical acquired shares in Fluidx Medical Technology with a $1.4 million investment (in addition to a prior $4.7 million investment), resulting in approximately 17% ownership and recorded as an equity investment due to the lack of significant influence over operations. " "